TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification

Oncogene

Volumn 29, Issue 32, 2010, Pages 4588-4598

  Zauner, L ^a   Melroe, G T ^a,d   Sigrist, J A ^a   Rechsteiner, M P ^a,c   Dorner, M ^a,e   Arnold, M ^a   Berger, C ^a   Bernasconi, M ^a   Schaefer, B W ^b   Speck, R F ^c   Nadal, D ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Burkitt's lymphoma; Epstein Barr virus; histone modification; Plasmodium falciparum; TLR9

Indexed keywords

B LYMPHOCYTE RECEPTOR; CPG OLIGODEOXYNUCLEOTIDE; HEMOZOIN; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; TOLL LIKE RECEPTOR 9;

ARTICLE; BURKITT LYMPHOMA; BZLF1 GENE; CONCENTRATION RESPONSE; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE EXPRESSION REGULATION; LYMPHOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; TRANSCRIPTION TERMINATION; VIRUS GENE;

ANIMALS; B-LYMPHOCYTES; BASE SEQUENCE; BURKITT LYMPHOMA; CELL DEATH; CELL LINE, TUMOR; CPG ISLANDS; HEMEPROTEINS; HERPESVIRUS 4, HUMAN; HISTONES; HUMANS; LIGANDS; MYELOID DIFFERENTIATION FACTOR 88; PLASMODIUM FALCIPARUM; PROMOTER REGIONS, GENETIC; PROTOZOAN PROTEINS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; VIRUS ACTIVATION;

HUMAN HERPESVIRUS 4; PLASMODIUM FALCIPARUM;

EID: 77955655130     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.203     Document Type: Article

References (41)

1. Alazard N, Gruffat H, Hiriart E, Sergeant A, Manet E. (2003). Differential hyperacetylation of histones H3 and H4 upon promoter-specific recruitment of EBNA2 in Epstein-Barr virus chromatin. J Virol 77: 8166-8172.
2. Ashman RF, Goeken JA, Drahos J, Lenert P. (2005). Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol 17: 411-420.
3. Berger C, Day P, Meier G, Zingg W, Bossart W, Nadal D. (2001). Dynamics of Epstein-Barr virus DNA levels in serum during EBV-associated disease. J Med Virol 64: 505-512.
4. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. (2003). NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol 77: 8532-8540.
5. Chene A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI et al. (2007). A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 3: e80.
6. Coban C, Igari Y, Yagi M, Reimer T, Koyama S, Aoshi T et al. (2009). Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe 7: 50-61.
7. Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S et al. (2005). Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 201: 19-25.
8. Cohen JI. (2000). Epstein-Barr virus infection. N Engl J Med 343: 481-492.
9. Countryman JK, Gradoville L, Miller G. (2008). Histone hyperace-tylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. J Virol 82: 4706-4719.
10. De Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749.
11. Di Renzo L, Altiok A, Klein G, Klein E. (1994). Endogenous TGF-beta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines. Int J Cancer 57: 914-919.
12. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL et al. (2005). Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 174: 5193-5200.
13. Flemington EK, Goldfeld AE, Speck SH. (1991). Efficient transcription of the Epstein-Barr virus immediate-early BZLF1 and BRLF1 genes requires protein synthesis. J Virol 65: 7073-7077.
14. Foster SL, Hargreaves DC, Medzhitov R. (2007). Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447: 972-978.
15. Heeg K, Dalpke A, Peter M, Zimmermann S. (2008). Structural requirements for uptake and recognition of CpG oligonucleotides. Int J Med Microbiol 298: 33-38.
16. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T et al. (2002). Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168: 4531-4537.
17. Ishii KJ, Koyama S, Nakagawa A, Coban C, Akira S. (2008). Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 3: 352-363.
18. Iwakiri D, Takada K. (2004). Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation. J Immunol 172: 1561-1566.
19. Jenkins PJ, Binne UK, Farrell PJ. (2000). Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol 74: 710-720.
20. Klein E, Kis LL, Klein G. (2007). Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 26: 1297-1305.
21. Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, Akira S et al. (2005). Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem 280: 8606-8616.
22. Kumagai Y, Takeuchi O, Akira S. (2008). TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev 60: 795-804.
23. Kurosaki T. (1999). Genetic analysis of B cell antigen receptor signaling. Annu Rev Immunol 17: 555-592.
24. Ladell K, Dorner M, Zauner L, Berger C, Zucol F, Bernasconi M et al. (2007). Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell Microbiol 9: 2055-2069.
25. Luka J, Kallin B, Klein G. (1979). Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94: 228-231.
26. Novak EJ, Rabinovitch PS. (1994). Improved sensitivity in flow cytometric intracellular ionized calcium measurement using fluo-3/Fura Red fluorescence ratios. Cytometry 17: 135-141.
27. Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, Visintin A et al. (2007). From the cover: malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 104: 1919-1924.
28. Peng SL. (2005). Signaling in B cells via Toll-like receptors. Curr Opin Immunol 17: 230-236.
29. Rechsteiner MP, Berger C, Weber M, Sigrist JA, Nadal D, Bernasconi M. (2007). Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells. J Gen Virol 88: 1454-1459.
30. Rechsteiner MP, Berger C, Zauner L, Sigrist JA, Weber M, Longnecker R et al. (2008). Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection. J Virol 82: 1739-1747.
31. Rickinson A, Kieff E. (2007). Epstein-Barr Virus. In: Knipe D, Howley P (eds). Fields Virology, Lippincott Williams & Wilkins: Philadelphia.
32. Rochford R, Cannon MJ, Moormann AM. (2005). Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol 3: 182-187.
33. Ryan JL, Fan H, Swinnen LJ, Schichman SA, Raab-Traub N, Covington M et al. (2004). Epstein-Barr virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol 13: 61-68.
34. Sanjuan MA, Rao N, Lai KT, Gu Y, Sun S, Fuchs A et al. (2006). CpG-induced tyrosine phosphorylation occurs via a TLR9-inde-pendent mechanism and is required for cytokine secretion. J Cell Biol 172: 1057-1068.
35. Takada K. (1984). Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 33: 27-32.
36. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. (2004). Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 16: 17-22.
37. Tovey MG, Lenoir G, Begon-Lours J. (1978). Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276: 270-272.
38. Tsurumi T, Fujita M, Kudoh A. (2005). Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 15: 3-15.
39. Yi AK, Peckham DW, Ashman RF, Krieg AM. (1999). CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol 11: 2015-2024.
40. Yuan J, Cahir-McFarland E, Zhao B, Kieff E. (2006). Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol 80: 2548-2565.
41. zur Hausen H, O'Neill FJ, Freese UK, Hecker E. (1978). Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 272: 373-375.